Race Oncology Ltd. (AU:RAC) has released an update.
Daniel Sharp Phillip Lynch, a director at Race Oncology Ltd., has ceased his directorship as of September 1, 2024, according to their Final Director’s Interest Notice. Before his departure, he held 2,000,000 options exercisable at $2.65, expiring in November 2025, and had indirect interests through Lynch Eventide Holdings with 450,606 ordinary shares and 64,371 piggyback options. This update is provided in compliance with listing rules and has been given to the ASX, reflecting changes in the company’s management structure.
For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.
